An interventional study of Empowerment and Navigation and SOC in Breast Cancer, sponsored by University of Illinois at Chicago. Recruiting at 1 site in United States. Open to female participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2026-03-10.
Sponsored by University of Illinois at Chicago · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Breast Neoplasms by University of Illinois at Chicago — 7 open to participants now, 8 under way, 1 of them phase 3. Breast Neoplasms · University of Illinois at Chicago.
Among the 15 studies in Breast Neoplasms by University of Illinois at Chicago, this one is the 2nd largest by planned enrollment, is one of 4 that started in 2023, is one of 6 with no phase, and was the 8th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →7 of the 15 studies in Breast Neoplasms by University of Illinois at Chicago are open now, in 1 country. Recruiting first, the newest first:
University of Illinois at Chicago · Sites in United States
Ages 25–99 · Women only
University of Illinois at Chicago · Sites in United States
Ages 18+
University of Illinois at Chicago · Sites in United States
Ages 18+
University of Illinois at Chicago · Sites in United States
Ages 25–99 · Women only
University of Illinois at Chicago · Sites in United States
Ages 18+ · Women only
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 30 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 4 · Phase 3 2
First in 1995; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 600 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 46 across the 15 interventional studies. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Illinois at Chicago is the lead sponsor of 496 studies on the registry; 115 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 19 (59%) have results posted.
2 of the studies in Breast Neoplasms by University of Illinois at Chicago that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07387445University of Illinois at ChicagoFeasibility and Acceptibility of a Multi-site Trial of Time Restircted Eating During Chemotheraply for Breast Cancer. | 2026-12-31 |
| NCT05483283University of Illinois at ChicagoEmpowering Vulnerable and Resilient Latinas to Obtain Breast Cancer Care | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies in Breast Neoplasms by University of Illinois at Chicago, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The investigator and study staff will identify, recruit and randomize Latina participants with elevated genetic and Social Determinants of Heath (SDH) risks. Within 1 week of enrollment, all Latina Aim 1 participants in both study arms will engage in three 30-minute, individual, phone-based sessions with the study team across 3 consecutive weeks
The investigator and study staff will identify, recruit and randomize Latina participants with elevated genetic and Social Determinants of Heath (SDH) risks. Within 1 week of enrollment, all Latina Aim 1 participants in both study arms will engage in three 30-minute, individual, phone-based sessions with the study team across 3 consecutive weeks. Sessions will be based on landline or cellphone calls. Within 1 week after each session, all Latina Aim 1 participants will receive copies of the multi-media materials (e.g., personalized plans) by text message or mail, depending on participants' preferences
Control Sessions will be as follows:
Session 1 Learning about Breast Cancer (BC) care uptake Targets the effects of Social Determinants of Heath (SDH) and genetic risk factors on Non-Latino White (NLW) Latino BC disparities Study staff will give personnel testimonials, empirical data and individual action plans behavior change and BC care uptake Session 2 Learning about Diet to promote BC prevention per the American Cancer Society (ACS) BC screening and prevention guidelines Session 3 Learning about Physical Activity to promote BC prevention
Empowerment and Navigation Sessions will be as follows:
Session 1 Learning about Breast Cancer (BC) care uptake Targets the effects of SDH and genetic risk factors on NLW/Latino BC disparities ACS BC screening and prevention guidelines Identify and address SDH and genetic risk factors Study staff will give personnel testimonials, empirical data and individual action plans for behavior change Session 2 Teaching about BC Targets the importance of sharing BC information and personal barriers \& preferred solutions to sharing BC information Study staff will give personnel testimonials and individual action plans for sharing information and role playing activities Session 3 Teaching about BC Targets opportunities \& skills in sharing BC information participants will give testimonials and relay empirical data. There will be a group discussion and plans for sharing information
There will be a post intervention BC survey call and an end of study BC survey call
Bicultural, bilingual study staff will engage participants in a 5-10 minute call/text every month to "check in" until the end of the study
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Aim 1
Aim 2
Aim 3
Exclusion Criteria:
Aim 1 and Aim 2 Not meeting at least one of the inclusion criteria
Aim 3
Empowerment and Navigation
Other: Empowerment and Navigation
Standard of Care (SOC)
Other: SOC
Empowerment and Navigation
SOC
Empower and navigation versus SOC
Number of participants that undergo risk-based BC screening per ACS guidelines versus the control group
Time frame: 4 years
Empower and navigation versus SOC
Number of participants that undergo recommended genetic services versus the control group
Time frame: 4 years
Started Jan 2023 (actual). Primary completion is estimated for Sep 2027, 56 months after the start.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 56 months is above that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Illinois at Chicago →